Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody–drug conjugates

帕妥珠单抗 突变 结合 药品 药物设计 计算生物学 遗传学 生物 曲妥珠单抗 药理学 生物信息学 数学 癌症 基因 数学分析 乳腺癌
作者
Xuefei Bai,Lingyi Xu,Zhe Wang,Xinlei Zhuang,Jiangtao Ning,Yanping Sun,Haibin Wang,Yugang Guo,Yingchun Xu,Jiangtao Guo,Shuqing Chen,Liqiang Pan
出处
期刊:Proceedings of the National Academy of Sciences of the United States of America [Proceedings of the National Academy of Sciences]
卷期号:122 (1)
标识
DOI:10.1073/pnas.2413686122
摘要

Recurrent missense mutations in the human epidermal growth factor receptor 2 (HER2) have been identified across various human cancers. Among these mutations, the active S310F mutation in the HER2 extracellular domain stands out as not only oncogenic but also confers resistance to pertuzumab, an antibody drug widely used in clinical cancer therapy, by impeding its binding. In this study, we have successfully employed computational-aided rational design to undertake directed evolution of pertuzumab, resulting in the creation of an evolved pertuzumab variant named Ptz-SA. This variant, with only two mutations (T30S/D31A) located on its heavy chain, effectively reinstates binding to the mutated antigen, at the expense of a 35-fold reduction in binding affinity to HER2 (S310F) compared to the wild-type pair. Subsequently, Ptz-SA demonstrates potent killing capacity through antigen-dependent cytotoxicity. Moreover, upon engineering Ptz-SA into antibody–drug conjugates, such as Ptz-SA-MMAE, it manifests notable in vitro and in vivo antitumor efficacy by efficiently delivering cytotoxic payload into tumor cells expressing HER2 (S310F). Cryoelectron microscopy studies elucidate the molecular mechanism underlying the restored binding ability of Ptz-SA toward the S310F mutation. The steric hindrance induced by the S310F mutation is efficiently circumvented by the T30S and D31A mutations, which provides adequate space to accommodate the larger phenylalanine. Additionally, Ptz-SA also exhibits binding capacity to HER2 (S310Y), another mutation occurring at the S310 site of HER2 with high frequency. The computational-aided evolution of pertuzumab provides an alternative strategy for overcoming point mutation-mediated resistance to therapeutic antibodies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈哈完成签到,获得积分10
1秒前
2秒前
2秒前
chinbaor完成签到,获得积分10
3秒前
sci帝国发布了新的文献求助10
3秒前
kk完成签到 ,获得积分10
4秒前
flyfish完成签到,获得积分10
5秒前
机智的笑槐给聪慧的致远的求助进行了留言
6秒前
10秒前
YHQ发布了新的文献求助10
10秒前
热塑性哈士奇完成签到,获得积分10
13秒前
一一完成签到 ,获得积分10
13秒前
橙尘尘完成签到,获得积分10
15秒前
17秒前
18秒前
LIU完成签到,获得积分20
19秒前
Doctor_wan89发布了新的文献求助30
22秒前
23秒前
迪奥哒发布了新的文献求助10
24秒前
zhanglh完成签到 ,获得积分10
25秒前
duanqianqian发布了新的文献求助10
27秒前
LIU发布了新的文献求助10
30秒前
明理剑心完成签到,获得积分10
30秒前
明理苑博完成签到,获得积分10
30秒前
30秒前
jyy应助浮生采纳,获得10
32秒前
34秒前
体贴花卷发布了新的文献求助10
36秒前
36秒前
白色杏林糖完成签到,获得积分10
37秒前
12完成签到 ,获得积分10
37秒前
38秒前
Kelvin.Tsi完成签到 ,获得积分10
38秒前
彭于晏应助刻苦的安白采纳,获得10
39秒前
无语的采柳完成签到 ,获得积分10
41秒前
fillippo99应助乐乐乐乐采纳,获得20
41秒前
温柔画笔应助123放羊娃456采纳,获得10
42秒前
普萘洛尔发布了新的文献求助10
43秒前
快乐的秋翠完成签到,获得积分10
43秒前
43秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Effect of reactor temperature on FCC yield 2000
Introduction to Spectroscopic Ellipsometry of Thin Film Materials Instrumentation, Data Analysis, and Applications 1200
How Maoism Was Made: Reconstructing China, 1949-1965 800
Medical technology industry in China 600
ANSYS Workbench基础教程与实例详解 510
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3312259
求助须知:如何正确求助?哪些是违规求助? 2944883
关于积分的说明 8521919
捐赠科研通 2620620
什么是DOI,文献DOI怎么找? 1432965
科研通“疑难数据库(出版商)”最低求助积分说明 664797
邀请新用户注册赠送积分活动 650134